US Material Events SEC 8-K Filings — May 04, 2026

04-05-2026

Global Net Lease, Inc. (GNL) announced a definitive all-stock merger agreement to acquire Modiv Industrial, Inc. (MDV) in a transaction valued at an enterprise value of approximately $535 million, expected to be immediately 4% accretive to GNL's AFFO per share while remaining leverage-neutral with no external capital required. Modiv shareholders will receive 1.975 GNL shares per Modiv share, equating to $18.82 per share (17% premium to May 1, 2026 closing price), resulting in GNL shareholders owning 89% of the combined company. The acquisition adds high-quality industrial net-lease assets with 15.0-year weighted average lease term and 45% investment-grade tenants, extending GNL's portfolio lease term to 7.0 years pro forma from 6.1 years.

• ·Transaction expected to close in Q3 2026, subject to Modiv stockholder approval (no GNL stockholder approval required).
• ·Modiv's portfolio adjusted for previously disclosed dispositions of Northrop Grumman and Kalera properties as of Dec 31, 2025.
• ·GNL to repay all Modiv debt and preferred stock using Revolving Credit Facility and cash on hand.

04-05-2026

Publix Super Markets announced Executive Chairman Todd Jones' intent to retire effective May 31, 2026, while he will continue as chairman of the board of directors. CEO Kevin Murphy commended Jones' 46-year career, leadership, and contributions including championing food donation campaigns that reached 1 billion pounds donated in 2025. Publix, the largest U.S. employee-owned company with over 260,000 associates and 1,434 stores across eight states, expressed confidence in its ongoing leadership and mission.

• ·Jones began career in 1980 as a front-service clerk; promoted to store manager (1988), district manager (1997), regional director (1999), VP Jacksonville Division (2003), SVP product business development (2005), president (2008), CEO and President (2016), CEO (2019), Executive Chairman (2024).
• ·Received George W. Jenkins Award for Excellence in 1994.
• ·Jones serves on boards of Florida Council of 100 and Fish and Wildlife Foundation of Florida; former FMI board member; inducted into Tampa Bay Business Hall of Fame.
• ·Publix operates stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina, Virginia, and Kentucky.
• ·Recognized by Fortune as a great place to work for 29 consecutive years.

04-05-2026

Phreesia, Inc. and its affiliates, including AccessOne Funding, LLC (Seller), AccessOne MedCard, Inc. (Servicer), and AccessOne Holdings, Inc. (Performance Guarantor), entered into Amendment No. 9 to the Receivables Purchase and Administration Agreement with PNC Bank, National Association (Purchaser and Administrative Agent) and PNC Capital Markets LLC (Structuring Agent), effective April 30, 2026. Concurrently, an Amended and Restated Fee Letter and Amended and Restated Performance Guaranty were executed, with Phreesia directly participating in the Performance Guaranty. The parties confirmed no Events of Termination or defaults, ratifying the agreement with representations of ongoing compliance and binding obligations.

• ·Original Receivables Purchase and Administration Agreement dated March 31, 2020
• ·Effectiveness conditions include payment of Upfront Fee (per Fee Letter), fees/expenses (including Mayer Brown LLP invoices dated December 30, 2025, March 12, 2026, and April 29, 2026), and delivery of specified documents
• ·Governed by New York law with jurisdiction in New York courts

04-05-2026

On April 28, 2026, SG Echo LLC, a wholly-owned subsidiary of Olenox Industries Inc. (formerly Safe & Green Holdings Corp., ticker SGBX), filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the Eastern District of Oklahoma to pursue a court-administered reorganization plan. The filing triggered an event of default, accelerating approximately $4 million (plus accrued interest) in obligations under the Loan and Security Agreement with Enhanced Capital Oklahoma Rural Fund, LLC, though enforcement is automatically stayed. While the parent company and other affiliates continue normal operations, and the debtor plans to operate as debtor-in-possession during the process.

• ·Bankruptcy case number: 26-80385
• ·Court: United States Bankruptcy Court for the Eastern District of Oklahoma, Muskogee, OK
• ·Creditors' meeting: June 1, 2026 at 10:00 AM (telephonic)
• ·Proof of claim deadlines: July 12, 2026 (non-governmental), October 29, 2026 (governmental)
• ·Deadline for complaint to except debt from discharge: July 31, 2026

04-05-2026

Great Elm Capital Corp. (GECC) reported Q1 2026 NII of $5.0 million ($0.36 per share), up approximately 13% QoQ from $4.4 million ($0.31 per share), supported by a $2.8 million incentive fee waiver, while total investment income declined to $9.5 million from $12.6 million QoQ and NAV dropped to $7.74 per share ($107.5 million) from $8.07 ($112.9 million) due to $5.7 million in net unrealized losses. The Board appointed Jason Reese as CEO effective May 4, 2026, called or repurchased all $57.5 million GECCO notes due June 2026, repurchased ~1% of shares (0.1 million) for $0.5 million at a 36% discount to NAV, and declared a $0.25 per share Q2 dividend yielding 18% annualized on May 1 closing price. Liquidity is strong with ~$10 million cash/equivalents, $50 million revolver availability, and asset coverage at 161.8%.

• ·Less than 1% of investments on nonaccrual as of March 31 2026
• ·Asset coverage ratio 161.8% as of March 31 2026 (vs 158.1% Dec 31 2025)
• ·GECM waives all incentive fees through June 30 2026
• ·$1.2 million additional distribution from CoreWeave post quarter-end
• ·$9.5 million remaining capacity under share repurchase program
• ·Conference call scheduled May 5 2026 at 8:30 AM ET

04-05-2026

WEX Inc. announced a cooperation agreement with activist investor Impactive Capital Master Fund LP, under which the company will nominate three new independent directors—Kurt Adams, Ellen Alemany, and Lauren Taylor Wolfe—for election at the 2026 Annual Meeting of Stockholders, now rescheduled to May 14, 2026. The board will expand to 11 members, including existing nominees Daniel Callahan, Aimee Cardwell, David Foss, James Groch, Derrick Roman, Melissa Smith, Stephen Smith, and Susan Sobbott, and post-meeting, the roles of Chair and CEO will separate with Melissa Smith continuing as CEO. Impactive will withdraw its competing nomination and support the company's slate amid customary standstill and voting commitments.

• ·New Directors will serve on the Board’s Nominating and Governance, Leadership Development and Compensation, Technology and Cybersecurity, and Finance and Audit Committees.
• ·Impactive will withdraw its nomination notice and support the revised Board slate.
• ·Additional proxy materials reflecting the revised slate of 11 nominees to be filed with the SEC; shareholders previously voting on Impactive’s white proxy card must submit new instructions on WEX’s blue proxy card.

04-05-2026

Lisata Therapeutics, Inc. entered into an Amendment and Waiver to its March 6, 2026 Merger Agreement with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser), extending the tender offer commencement deadline from 26 to 59 business days due to Parent's delay, which highlights execution risks in the acquisition process. Parent will make non-refundable Interim Operating Payments totaling $1.1 million to cover Lisata's expenses during the delay, while Lisata waives related claims upon payment and offer commencement. The waiver period runs until May 29, 2026, with cooperation required to avoid further delays.

• ·Waiver Period: From May 3, 2026, until May 29, 2026
• ·Offer commencement extended to 59 Business Days after March 6, 2026
• ·Lisata may terminate waiver sections if Parent misses payments or commits material breach uncured within 2 Business Days
• ·Interim payments terminate upon Offer commencement or Merger Agreement termination

04-05-2026

Blueport Acquisition Ltd (Nasdaq: BPAC), a SPAC, and SingAuto Inc announced a definitive business combination agreement valued at $1.2 billion, under which SingAuto shareholders will receive approximately 120,000,000 ordinary shares of the resulting PubCo at $10.00 per share. The transaction involves a reincorporation merger followed by an acquisition merger, with closing expected by end of 2026 subject to regulatory approvals, shareholder votes, SEC review of the proxy/prospectus, and Nasdaq listing. No financial performance metrics or declines are disclosed, though forward-looking statements highlight execution risks including potential failure to close or realize benefits.

• ·SingAuto headquartered in Singapore, operates in Singapore and Middle East, focuses on CEVs for cold-chain logistics including frozen, chilled, fresh produce, and pharmaceuticals.
• ·Transaction unanimously approved by boards of both companies.
• ·Advisors: Loeb & Loeb LLP and Ogier (Blueport); Robinson & Cole LLP, ShookLin & Bok, Ogier (SingAuto).
• ·Form F-4 registration statement to be filed including proxy statement/prospectus.
• ·Filing references Blueport's Form 10-K for FY ended December 31, 2025, filed February 26, 2026.

04-05-2026

TG-17, Inc. (OBAI), through its CEO Doron Kempel, filed Amendment No. 1 to the Certificate of Designations, Preferences and Rights of its Series C Convertible Preferred Stock, originally filed on September 16, 2025. The amendment, approved by the Board of Directors and requisite shareholders on May 4, 2026, adds a new Section 4(f) imposing a leak-out restriction: holders collectively cannot sell more than 10% of daily trading volume in conversion shares, unless sold at or above 115% of the prior day's closing sale price. All other provisions remain unchanged.

• ·Amendment executed pursuant to Nevada Revised Statutes Section 78.1955
• ·Original Certificate of Designations filed September 16, 2025

04-05-2026

Global Net Lease, Inc. (GNL) has entered into a definitive merger agreement to acquire Modiv Industrial, Inc. in an all-stock transaction with an enterprise value of approximately $535 million, offering Modiv common stockholders 1.975 GNL shares per Modiv share, equating to $18.82 per share—a 17% premium to Modiv's May 1, 2026 closing price and 28% to its unaffected price. The transaction is expected to be immediately 4% accretive to GNL's AFFO per share, leverage-neutral with $6 million in annual synergies, and extend GNL's weighted average lease term from 6.1 years to 7.0 years pro forma, while providing Modiv stockholders a 25% dividend increase. Closing is anticipated in Q3 2026, subject to Modiv stockholder approval, with GNL stockholders owning 89% of the combined entity.

• ·Transaction structured as all-stock, leverage-neutral; GNL to repay Modiv debt and preferred stock using revolver and cash on hand.
• ·Modiv portfolio: 45% investment-grade tenants (23% actual, 22% implied), geographically diversified across U.S. industrial markets.
• ·No changes to GNL executive management or Board; Modiv stockholder approval required, no GNL approval needed.
• ·Advisors: BMO Capital Markets (GNL financial), Truist Securities (Modiv financial).

04-05-2026

Collective Acquisition Corp. II priced its initial public offering at $220,000,000, consisting of 22,000,000 units at $10.00 per unit, with units to list on Nasdaq under 'CAIIU' starting April 29, 2026, and closing expected on April 30, 2026. Each unit includes one Class A ordinary share and one-half redeemable warrant exercisable at $11.50 per share. The blank check company, led by CEO Daniel Hoffman and Chairman Samuel Sayegh, focuses on mergers in sectors like defense technology and AI, with underwriters granted an option for 3,300,000 additional units.

• ·Units expected to separate for individual trading as 'CAII' (shares) and 'CAIIW' (warrants)
• ·Underwriter: Clear Street LLC (sole book-running manager)
• ·Legal counsel: Reed Smith LLP (Company), Walkers (Cayman) LLP (Cayman counsel), Morgan, Lewis & Bockius LLP (underwriters)
• ·Registration statement effective April 28, 2026
• ·45-day over-allotment option

04-05-2026

Aura Biosciences appointed Natalie Holles as Chief Executive Officer, President, and Board member effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who stepped down from her roles. The Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma has enrolled 86 patients as of May 4, 2026, with over 25 additional patients scheduled or identified for screening through May 2026, on track for enrollment completion by mid-2026 and topline data in the second half of 2027. No declines or flat performance metrics were reported.

• ·CoMpass trial is under Special Protocol Assessment agreement with FDA and has Orphan Drug Designation from FDA and EMA, plus Fast Track designation from FDA.
• ·Natalie Holles has over 25 years of experience, including prior CEO roles at Third Harmonic Bio and Audentes Therapeutics.

04-05-2026

Apimeds Pharmaceuticals US, Inc. entered into a Settlement Agreement on April 24, 2026, resolving disputes from a prior Merger Agreement, under which Lokahi Therapeutics retains the Apitox program and provides a $4M working capital contribution plus forgiveness of a $750k advance, while the Company forms Newco and distributes 51% of Lokahi stock. Concurrently, a Forbearance Agreement with Alto Opportunity Master Fund grants temporary relief from defaults on an $11M convertible note until June 30, 2026, subject to strict conditions including timely 10-K filing and NYSE compliance. However, the Side Letter allows potential merger unwind if the 10-K is delayed past April 30, 2026 or receives a qualified audit opinion, and board changes introduce interim uncertainty with Mr. Koo's resignation and planned transition to new directors.

• ·Irrevocable proxy granted by Inscobee Parties to Dr. Vin Menon and Captain Sandeep Singh Yadav until the later of NYSE approval, Preferred Stock Conversion, NYSE denial, or July 30, 2026.
• ·Newco to receive 10% of net financing proceeds from Company's existing investor arrangement; spin-off expected within 12 months, extendable by another 12 months.
• ·Forbearance Conditions include 10-K filing by April 30, 2026, registration statement effective by June 30, 2026, 1-for-10 reverse stock split, and NYSE compliance by June 30, 2026.
• ·Stockholder Consents purporting to remove directors declared void; board temporarily reduces to three members during Interim Period until 10-K filing.

04-05-2026

George Furlan resigned as Director and Interim Chief Executive Officer effective April 24, 2026, with the resignation accepted by the Board on May 1, 2026, and no disagreements on company operations, policies, or practices. The Board, now consisting of Eric Bruns (Chairman) and Dionne Harvey Pendleton, designated Serge Knazev (President and COO since January 1, 2026) as Acting Principal Executive Officer effective May 1, 2026, pending searches for a permanent CEO and new director. Compensation owed to Mr. Furlan for periods ended December 31, 2025, and March 31, 2026, is under review, with no separation agreement entered as of the filing date.

• ·Resignation informed telephonically on April 24, 2026; written notice received April 29, 2026.
• ·Company will amend this 8-K within four business days if material separation terms are determined for Mr. Furlan.

04-05-2026

Cabaletta Bio, Inc. (CABA) announced the pricing of an underwritten public offering of 51,725,000 shares of common stock at $2.90 per share, expected to generate approximately $150 million in aggregate gross proceeds before expenses. The offering includes participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, Eli Lilly and Company, and other investors, with TD Cowen, Guggenheim Securities, and Cantor as joint book-running managers. The offering is expected to close on or about May 5, 2026, subject to customary conditions.

• ·Offering priced at $2.90 per share, representing the at-the-market price under Nasdaq rules.
• ·All shares sold by Cabaletta; pursuant to shelf registration on Form S-3-ASR (File No. 333-278126), effective March 31, 2025.
• ·Headquarters and labs located in Philadelphia, PA.

04-05-2026

CNS Pharmaceuticals, Inc. entered into a private placement with institutional investors for 650,000 shares of common stock at $2.30 per share and pre-funded warrants to purchase 9,143,479 shares at $2.299 per warrant, expecting gross proceeds of approximately $22.5 million before fees for acquiring new assets and general corporate purposes. Jerzy (George) Gumulka resigned from the Board without any disagreements, and Michal Fisher was appointed as an independent director with extensive life sciences experience. The offering includes a 120-day lock-up on equity sales and restrictions on variable rate transactions for one year.

• ·Closing of offering expected on May 5, 2026, subject to customary conditions.
• ·Registration statement for resale of shares to be filed within 15 days of closing, effective within 60 days (or 90 days if reviewed).
• ·No equity sales or variable rate transactions for 120 days post-registration effectiveness (with exceptions), and no variable rate transactions for one year post-closing.

04-05-2026

Apellis Pharmaceuticals, Inc. amended and restated its Executive Separation Benefits and Retention Plan (A&R Separation Benefits Plan) effective upon the closing of its merger with Biogen Inc., as per the Merger Agreement. The amendments accelerate vesting of Converted Options and Converted RSU Awards for participants, including named executive officers, upon termination without cause or resignation for good reason, and modify the 'Good Reason' definition for C-Level Officers to not exclude changes due to becoming a subsidiary. No financial impacts or performance metrics are disclosed in the filing.

• ·Amendments apply to all participants including named executive officers.
• ·Plan effective on Closing Date of Merger Agreement.
• ·Date of earliest event: April 28, 2026; Filing Date: May 4, 2026.

04-05-2026

SunOpta Inc. (Nasdaq: STKL, TSX: SOY) completed its acquisition by an affiliate of Refresco Holding B.V. for US$6.50 per Common Share in cash on May 1, 2026, following shareholder approval on April 16, 2026, and a final court order on April 22, 2026. SunOpta's shares will be delisted from the TSX and Nasdaq, it will cease to be a reporting issuer under Canadian securities laws, and deregister under U.S. securities laws. While the transaction provides immediate cash to shareholders, forward-looking statements highlight risks including potential business disruptions, employee retention issues, litigation, and operating costs exceeding expectations.

• ·Registered shareholders must submit letter of transmittal and share certificates/DRS advices to TSX Trust Company to receive Consideration.
• ·SunOpta has over 50 years of expertise in customized supply chain solutions for beverages, broths, and better-for-you snacks.

04-05-2026

Ecovyst Inc., as Purchasers’ Guarantor, along with its subsidiaries New Structure Subco Inc. (US Purchaser) and EV Industrial Chemical Subsidiary Holdings Inc. (Canadian Purchaser), entered into a Share Purchase Agreement dated May 1, 2026, to acquire the entire issued share capital of INEOS Calabrian Holdings Corp. and INEOS Calabrian Corporation Canada, Inc. from INEOS sellers, including INEOS Calabrian Holdings Limited and INEOS Calabrian Canada Holdings Limited. The transaction involves the business of developing, manufacturing, marketing, distributing, and selling on-purpose SO2 and derivatives (SMBS, SBS, STS), subject to conditions including warranties and a MAC condition, with completion arrangements outlined but no purchase price disclosed in the filing. INEOS Enterprises Holdings Limited acts as Sellers’ Guarantor.

• ·Agreement dated May 1, 2026; SEC filing date May 4, 2026.
• ·Accounts Date: 31 December 2025.
• ·Conditions include Warranty Condition and MAC Condition (incomplete in excerpt).

04-05-2026

Track Group, Inc. completed a comprehensive recapitalization and debt refinancing, reducing net debt by ~$27 million (~63% decrease) and net leverage from 7.2x to 2.6x through a $21 million 5-year term loan, $10.3 million PIPE financing (29,471,429 shares at $0.35/share), and discounted debt settlements. Debt maturity extended to 5 years with anticipated annual cash interest savings of ~$200,000. The board was reconstituted with new directors including Denver Smith as Chairman, representing ~75% of go-forward ownership for enhanced alignment.

• ·New credit facility includes 0% mandatory amortization in years 1-2, 5% thereafter.
• ·PIPE participants: TRCK Management (1.5%), CRC (49.25%), JCP (49.25%).
• ·Legal counsel: Disclosure Law Group and Winston & Strawn LLP (Company); Olshan Frome Wolosky LLP and Steptoe & Johnson PLLC (CRC/JCP).

04-05-2026

Madison Square Garden Sports Corp. appointed Paul DiCicco, aged 51 with prior CFO experience at Stephen Gould Corporation and roles at Harris Blitzer Sports and Entertainment LLC, as Executive Vice President, Chief Financial Officer, and Treasurer effective May 11,

04-05-2026

G-III Apparel Group's Compensation Committee awarded performance share units (PSUs) to five Named Executive Officers under the 2023 Long-Term Incentive Plan, totaling 259,115 PSUs, with vesting tied to three-year performance metrics for fiscal 2027-2029. Vesting is weighted 75% on cumulative Adjusted EBIT and 25% on average ROIC (after 28.5% hypothetical tax), adjustable from 0% to 150% of target based on achievement levels. Settlement of vested PSUs will occur on or within 90 days after April 15, 2029, subject to continued service.

• ·PSU vesting requires achievement of minimum thresholds for each metric; none vest if below minimum.
• ·Adjustments to GAAP results may apply for Adjusted EBIT and ROIC calculations in specified situations.
• ·PSU share count adjustable for stock splits, dividends, and other extraordinary corporate events.

04-05-2026

SilverBox Corp IV, a SPAC, entered into a First Amendment to its Business Combination Agreement originally dated August 6, 2025, with Parataxis Holdings LLC, Parataxis Holdings Inc., and related merger subs and representatives. The amendment extends the Outside Date for terminating the agreement if closing conditions are not met from the original date to August 6, 2026, providing additional time to complete the transaction. No financial terms or other provisions of the original agreement were modified.

• ·Original Business Combination Agreement dated August 6, 2025
• ·First Amendment dated as of May 1, 2026
• ·Amendment filed as Exhibit 2.1 in 8-K on May 4, 2026 under Items 1.01 and 9.01

04-05-2026

At the annual stockholder meeting on April 30, 2026, Intuitive Surgical's shareholders elected all ten Board nominees with overwhelming support (e.g., David J. Rosa received 282,229,466 For votes), approved the advisory say-on-pay for named executive officers (265,030,878 For), ratified PricewaterhouseCoopers LLP as independent auditors (308,789,950 For), and approved the Amended 2010 Incentive Award Plan, increasing shares reserved from 120,350,000 to 125,350,000 and extending the term to January 29, 2036. The Board also increased the common stock repurchase program authorization to an aggregate of $5.0 billion. All proposals passed decisively with minimal opposition.

• ·Proposal 2 Against votes: 17,018,702
• ·Proposal 4 Against votes: 22,129,032 (highest opposition among proposals)

04-05-2026

Flag Ship Acquisition Corporation (SPAC), Great Future Technology Inc., and GFT Merger Sub Limited entered into a Mutual Termination Agreement on May 3, 2026, terminating their prior Merger Agreement dated April 18, 2025 (as amended December 11, 2025) and all related ancillary agreements including lock-up, support, and registration rights agreements. The parties provided mutual releases of all claims related to the merger, subject to exclusions for surviving provisions and post-termination obligations. This development ends the proposed business combination with no further rights or liabilities under the original agreements.

• ·Termination effective May 3, 2026, in accordance with Section 9.01(a) of the Merger Agreement.
• ·Merger Agreement originally dated April 18, 2025, and amended December 11, 2025.
• ·Ancillary Documents automatically terminated: Parent Shareholder Lock-up and Support Agreement, Sponsor Lock-up Agreement, Sponsor Voting and Support Agreement, Amended and Restated Registration Rights Agreement.
• ·Each party responsible for its own expenses related to the Termination Agreement and original Merger Agreement.

04-05-2026

Valion Bio, Inc. (formerly Tivic Health Systems, Inc., Nasdaq: VBIO), a clinical-stage immunotherapeutics company, announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs on May 4, 2026. Ms. Lackey brings nearly two decades of experience in biopharmaceutical legal matters, IP strategy, and Nasdaq governance from roles at Alaunos Therapeutics, Kuur Therapeutics, and firms like Winston & Strawn LLP. The hire supports advancing Entolimod™ toward FDA Animal Rule approval for Acute Radiation Syndrome, scaling CDMO subsidiary Velocity Bioworks, and executing capital raises.

• ·Entolimod™ has received Fast Track and Orphan Drug designations from the FDA.
• ·Ms. Lackey's early career included roles as Research Associate at University of Texas Health Science Center at Houston and Research Technician at UT MD Anderson Cancer Center.
• ·J.D. from University of Houston Law Center.
• ·Investor contact: Rich Cockrell, CG Capital.

04-05-2026

Allied Gaming & Entertainment Inc. entered into a Share Issuance and Reimbursement Agreement with CEO Yangyang Li, providing for conditional issuance of shares equal to 25% of the company's estimated maximum exposure under a $5,936,738.36 guaranty to Knighted Pastures, LLC (at $0.30/share) in recognition of his personal guaranty, plus unconditional reimbursement of any payments made by him at 8.75% interest. Separately, the company agreed to grant General Counsel Xiao Yundan up to 3,000,000 shares worth $900,000 under the 2019 Equity Incentive Plan as compensatory equity to address compensation gaps and promote retention, subject to vesting and conditions. Both issuances are contingent on special committee approval, fairness opinion, stockholder vote, Plan amendment, and Nasdaq compliance, with no shares issued yet.

• ·CEO share issuance conditioned on Special Committee approval with independent counsel and financial advisor fairness opinion.
• ·GC Award requires stockholder approval of Plan share reserve increase at next annual or special meeting.
• ·6-month lock-up on GC Award shares post each vesting date.
• ·Reimbursement obligation to CEO effective immediately and survives agreement termination.
• ·Guaranty dated April 10, 2026.

04-05-2026

MacroGenics, Inc. (Nasdaq: MGNX) entered into an expanded royalty purchase agreement with Sagard Healthcare Partners, receiving a $60 million upfront cash payment and eligibility for an additional near-term 2026 sales-based milestone of up to $20 million on future global net sales of ZYNYZ® (retifanlimab-dlwr). Under the terms, Sagard's capped royalty interest will revert to MacroGenics once Sagard receives total payments of 1.7x its investment by September 30, 2032, or 2.0x thereafter. MacroGenics retains its other economic interests in ZYNYZ, which is licensed to Incyte Corporation.

• ·Initial ZYNYZ royalty purchase agreement entered in June 2025.
• ·ZYNYZ is a PD-1 inhibitor indicated for specific cancer treatments including squamous cell carcinoma of the anal canal (SCAC) and Merkel cell carcinoma (MCC).

04-05-2026

Senseonics Holdings, Inc. entered into a Second Amendment to its Loan and Security Agreement on May 1, 2026, providing up to $140.0 million in senior secured term loans, including a $10.0 million Tranche 2 Loan to be funded at closing on May 6, 2026, and an expected $10.0 million Tranche 3A Loan, with additional tranches up to $95.0 million available subject to milestones. Loans mature on September 3, 2029, bear interest at the greater of prime rate plus 2.40% or 9.90%, and include issuance of warrants for 2.0% of funded amounts. The amendment involves prepayment fees of 3.0%-1.0% and various fees totaling $200,000 at closing plus tranche-specific fees.

• ·Interest-only payments through October 1, 2028, or Maturity Date if 2025 Tranche 3B Milestone met
• ·Additional Warrants exercisable through seventh anniversary or certain acquisitions
• ·Exercise price for warrants based on three-day VWAP prior to issuance

04-05-2026

Ekso Bionics Holdings, Inc. (EKSO) filed a Form 8-K on May 04, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), material modifications to rights of security holders (Item 3.03), and amendments to articles of incorporation or bylaws (Item 5.03). Exhibit 3.1 was attached, referencing an exhibit document (ex3-1.htm). No quantitative financial metrics or period-over-period comparisons were detailed in the provided content.

• ·Filing Items: 1.01, 3.02, 3.03, 5.03, 9.01
• ·Subcategory: Material Agreement Entry

04-05-2026

Damora Therapeutics, Inc. announced on April 28, 2026, that Chief Financial Officer Lori Firmani will depart effective May 1, 2026, receiving separation benefits including a $6,000 health savings account contribution, base salary continuation and pro-rated target bonus in a lump sum, and full acceleration of equity awards, subject to a release agreement. The Board appointed Brian Burkavage, current Senior Vice President of Finance, as the new principal financial officer and principal accounting officer effective the same date. No arrangements, family relationships, or material transactions involving Mr. Burkavage were disclosed.

• ·Lori Firmani served as principal financial officer and principal accounting officer since August 2024, prior to the Company's acquisition of privately-held Damora Therapeutics, Inc. in November 2025.
• ·Brian Burkavage joined the Company in December 2025 after serving as SVP Finance and Chief Accounting Officer at IO Biotech, Inc. (November 2021 to December 2025), Controller at Passage Bio, Inc. (2020-2021), Director of Financial Planning and Analysis at Aclaris Therapeutics, Inc. (2017-2020), and 11 years at Ernst & Young LLP.
• ·Separation benefits described in the Company's Definitive Proxy Statement on Schedule 14A filed April 28, 2026.
• ·Mr. Burkavage to enter standard indemnification agreement for executive officers.

04-05-2026

byNordic Acquisition Corp issued a $250,000 promissory note to Achilles Capital AB on April 29, 2026, which is due upon consummation of a Business Combination with no interest accruing. Repayment is limited to funds outside the Trust Account if no Business Combination occurs, with the Payee waiving any claims against the Trust Account. The note includes standard events of default, remedies, and is governed by New York law.

• ·Note treated as equity for U.S. tax purposes
• ·Payee waives all claims against Trust Account
• ·Prepayable at any time without penalty
• ·Governed by New York law

04-05-2026

Ameresco reported Q1 2026 revenue of $401.5 million, up 14% YoY, driven by 16% growth in Projects to $290.5 million and 22% in O&M to $30.2 million, while Awarded Project Backlog grew 20% to $2.8 billion; however, net loss attributable to common shareholders widened to $18.3 million from $5.5 million YoY due to higher net interest expenses and adverse weather impacts on RNG sites, with Adjusted EBITDA flat at $40.5 million. The company announced a $400 million strategic investment by HASI in its biogas business, forming Neogenyx Fuels JV, and updated 2026 guidance with revenue at $2.0-2.2 billion and Adjusted EBITDA $250-270 million reflecting 70% ownership. Total Revenue Visibility stands at $10.6 billion.

• ·Gross margin of 14% impacted by adverse weather at RNG sites.
• ·Non-GAAP Adjusted Cash from Operations Q1 2026: $62.0 million.
• ·8-quarter rolling average Non-GAAP Adjusted Cash from Operations: $57.0 million.
• ·Corporate Debt Leverage Ratio: 3.2X.
• ·Energy Debt Advance Rate: 73%.
• ·Q2 2026 guidance: Adjusted EBITDA $58-62 million, Non-GAAP EPS $0.18-0.23.
• ·FY 2026 expected capex: $300-350 million.

04-05-2026

Hercules Capital, Inc. (NYSE: HTGC) announced the promotion of Seth Meyer from CFO to President effective May 18, 2026, to oversee platform scaling and growth. Andrew Olson, a returning executive with 19 years of experience, was appointed as the new CFO and Head of Corporate Development on the same date. CEO Scott Bluestein highlighted the moves as strategic for accelerating growth and maintaining financial strength.

• ·Hercules common stock trades on NYSE under ticker HTGC.
• ·Andrew Olson previously served at Hercules from 2014 to 2017 in finance roles including Interim CFO.
• ·Seth Meyer has served as CFO since 2019.

04-05-2026

Lattice Semiconductor reported Q1 2026 revenue of $170.9 million, up 42.2% YoY from $120.2 million and 17.2% QoQ from $145.8 million, with record Compute & Communications revenue and Industrial & Embedded growth exceeding 20% QoQ. Non-GAAP gross margin reached 70.0% (up 100 bps YoY), non-GAAP EPS of $0.41 (up 86.2% YoY), and adjusted EBITDA margin of 39.6% (up 620 bps YoY); however, operating cash flow margin fell to 29.4% QoQ from 39.5%, and non-GAAP free cash flow margin declined to 23.2% QoQ from 30.2%. The company signed a definitive agreement to acquire AMI for $1.65 billion ($1.0 billion cash + $650 million stock), expected to close in Q3 2026 and be accretive to non-GAAP gross margin, FCF, and EPS.

• ·Q2 2026 revenue guidance: $175M to $195M (~50% YoY growth expected).
• ·Q2 2026 non-GAAP gross margin expected: 70% +/- 1%.
• ·Q2 2026 non-GAAP operating expenses expected: $64M to $67M.
• ·Q2 2026 non-GAAP EPS expected: $0.42 to $0.46.
• ·AMI acquisition expected accretive to non-GAAP gross margin, FCF, and EPS; supports $1B+ annual revenue run rate by Q4 2026.

04-05-2026

Effective April 28, 2026, Richard Akright resigned as Co-Chief Financial Officer of urban-gro, Inc., with the resignation not due to any disagreement on operations, policies, or accounting matters. Eric Sherb, previously the other Co-Chief Financial Officer, will now serve as the sole Chief Financial Officer. The 8-K was filed on May 4, 2026, and signed by Bradley Nattrass, Chairman and Chief Executive Officer.

• ·Company address: 1751 Panorama Point, Unit G, Lafayette, CO 80026
• ·Trading symbol: UGRO (Common Stock, par value $0.001 per share)

04-05-2026

Exxon Mobil Corporation announced on April 28, 2026, that Len M. Fox, Vice President, Controller and Tax (principal accounting officer), intends to retire effective July 1, 2026. The company simultaneously elected Susan Buchanan, age 44, as Vice President and Chief Accounting Officer (principal accounting officer) and Controller, effective July 1, 2026. Ms. Buchanan has held prior roles including President of ExxonMobil Global Business Solutions since February 2026.

• ·Susan Buchanan previously served as Vice President, Strategy and Business Development for ExxonMobil Upstream from October 2023 to February 2026.
• ·She was General Manager of the U.S. Conventional Upstream Business from November 2022 to October 2023.
• ·Prior roles include Manager, Upstream Strategy from April 2021 and positions in Treasurers and Controllers functions.
• ·Ms. Buchanan, like other executive officers, does not have an employment contract.
• ·Filing signed by Neil A. Hansen on May 4, 2026.

04-05-2026

Rein Therapeutics, Inc. (RNTX) announced the pricing of a $50 million underwritten public offering of 50 million shares of common stock at $1.00 per share, with gross proceeds of $50 million before expenses, and a 45-day underwriter option for an additional 7.5 million shares. The offering, expected to close on or about May 4, 2026, will fund the ongoing Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) through completion, working capital, and general corporate purposes, with net proceeds and existing cash sufficient into 2028. No declines or flat metrics reported.

• ·Offering closes on or about May 4, 2026, subject to customary conditions.
• ·Konik Capital Partners, LLC acting as sole book-running manager.
• ·LTI-03 has Orphan Drug Designation in the U.S.; LTI-01 has Orphan Drug Designation in U.S. and E.U., and Fast Track Designation in U.S.
• ·Registration statement on Form S-1 (File No. 333-295390) effective April 30, 2026.

04-05-2026

Alcoa Corporation and borrower Alcoa Nederland Holding B.V. executed Amendment No. 3 to their Revolving Credit Agreement dated September 16, 2016 (as previously amended), extending the Initial Scheduled Maturity Date from its prior date to June 27, 2028, with reaffirmation of security obligations by Loan Parties. JPMorgan Chase Bank, N.A. acted as Administrative Agent and lead arranger, with all Lenders consenting. A consent fee of 0.05% of each Lender's aggregate outstanding Commitment is payable on the effective date.

• ·Amendment No. 3 Effective Date upon satisfaction of conditions including signatures, officer certificate confirming no Default, organizational documents, legal opinions, KYC/AML compliance, and payment of fees/expenses.
• ·Post-closing: Certain Subsidiary Guarantors to take actions per Schedule 1 within specified periods.

04-05-2026

Sonos reported Q2 FY2026 revenue of $282 million, up 8% YoY from $260 million, with Adjusted EBITDA improving to $2 million from a $1 million loss, marking the first positive Q2 Adjusted EBITDA in four years. First half FY2026 revenue increased 2% YoY to $827 million, while Adjusted EBITDA rose 48% YoY to $134 million and GAAP gross margin improved to 45.7%. However, Q2 GAAP net loss was $29 million despite a $41 million YoY improvement, and Non-GAAP net loss was $3 million.

• ·Cash and cash equivalents increased to $200 million from $175 million at FY end.
• ·Operating cash flow for H1 FY2026 was $98 million, slightly up from $97 million YoY.
• ·Shareholders' equity rose to $384 million from $355 million at FY end.
• ·Ongoing IP litigation expenses against Alphabet and Google classified as non-GAAP adjustments.

04-05-2026

The Brink’s Company held its 2026 Annual Meeting on April 28, 2026, where shareholders elected nine directors to the Board for terms expiring in 2027, approved an advisory resolution on named executive compensation, ratified KPMG LLP as independent auditors for the fiscal year ending December 31, 2026, and approved the Amended and Restated 2024 Equity Incentive Plan adding 3,900,000 shares of common stock. A shareholder proposal requesting a report on employee retention rates by demographic categories was overwhelmingly rejected. All company proposals received strong shareholder support with minimal opposition.

• ·Proposal 1 (Director Elections): For votes ranged from 33,968,237 (Kathie J. Andrade) to 36,098,041 (Timothy J. Tynan); Against ranged from 264,874 to 2,281,591.
• ·Proposal 2 (Say-on-Pay): 35,902,479 For, 419,407 Against.
• ·Proposal 3 (Auditor Ratification): 38,023,925 For, 70,920 Against.
• ·Proposal 4 (Equity Plan): 35,301,445 For, 1,018,331 Against.
• ·Proposal 5 (Shareholder Proposal): 2,619,075 For, 33,439,945 Against.

04-05-2026

Ingevity Corporation held its Annual Meeting of Stockholders on April 29, 2026, where shareholders elected all nine director nominees with overwhelming support (over 95% FOR votes for most, ranging from 96.8% to 99.0%). Stockholders also approved the amendment to the 2025 Omnibus Incentive Plan increasing available shares by 580,000 (97.0% FOR), ratified PricewaterhouseCoopers LLP as auditors for fiscal 2026 (99.6% FOR), and approved named executive officer compensation on an advisory basis (89.3% FOR), with a quorum of 95.10% of 35,222,538 shares outstanding.

• ·Detailed director voting: Luis Fernandez-Moreno (31,173,836 FOR, 862,109 WITHHELD); Diane H. Gulyas (31,183,123 FOR, 852,804 WITHHELD); all others similarly high FOR votes with minimal opposition.
• ·Executive compensation vote: 28,593,615 FOR, 3,435,921 AGAINST, 25,712 ABSTAIN, 1,443,084 broker non-votes.
• ·Auditor ratification: 33,358,881 FOR, 118,571 AGAINST, 20,880 ABSTAIN.
• ·Plan amendment: 31,038,374 FOR, 990,650 AGAINST, 26,224 ABSTAIN, 1,443,084 broker non-votes.

04-05-2026

BARK, Inc. (NYSE: BARK) announced the immediate appointment of James Gagne, a logistics executive with over 30 years of experience, to its Board of Directors. Mr. Gagne previously served as CEO of SEKO Logistics from 2017 to 2024, scaling the company from operations in three countries and $400M in revenue to 60 countries and $2.4B in revenue. CEO Matt Meeker praised Gagne's supply chain expertise as key to supporting BARK's operations.

• ·James Gagne holds a B.S. from the U.S. Merchant Marine Academy and speaks Mandarin Chinese.
• ·BARK was founded in 2011.
• ·Reference to Q4 FY26 10-Q filed February 5, 2026, for risk factors.

04-05-2026

New Mountain Finance Corp reported stable adjusted net investment income of $32.2 million or $0.32 per share for Q1 2026, flat YoY, amid portfolio enhancements and a ~$470 million Secondary Sale completed on March 10, 2026. However, NAV per share declined to $10.92 from $11.52 at December 31, 2025, reflecting the sale, market movements in software loans, and net realized/unrealized losses leading to a $(0.51) per share loss from operations versus $0.22 profit in Q1 2025. The company repurchased ~$66 million of shares YTD at $8.01 average, announced $50 million additional repurchase authorization (remaining capacity ~$80 million), and reduced debt cost on Holdings Credit Facility.

• ·Portfolio composition: 64.7% First Lien, 16.6% Senior Loan Funds (SLP III & IV) & NMNLC, 19.7% other.
• ·91.4% of portfolio fair value rated Green on internal Risk Rating as of March 31, 2026.
• ·Weighted average YTM at Cost of 11.1% as of March 31, 2026.
• ·Reduced cost of debt from SOFR + 1.95% to SOFR + 1.85% on Holdings Credit Facility.
• ·$692.1 million available capacity on credit facilities as of March 31, 2026.
• ·Q2 2026 distribution of $0.25 per share payable June 30, 2026 to holders of record June 16, 2026.

04-05-2026

Reliance Global Group, Inc. (Nasdaq: EZRA), through its biotech arm LifeSci Global, completed a strategic $2.0 million investment in Innervate Radiopharmaceuticals, acquiring 421,053 shares at $4.75 per share with $500,000 funded at closing and the right to accelerate further funding. The investment targets Innervate's late-stage 18F-mFBG PET imaging agent for neuroblastoma, presenting a $250 million initial market opportunity, with potential expansion into cardiovascular and neurodegenerative markets each exceeding $1 billion, alongside Priority Review Voucher upside. While offering transformative exposure to high-growth radiopharmaceuticals (U.S. sales >$2 billion, global >$5 billion), success depends on regulatory approval and commercialization, with no assurances provided.

• ·Investment approved by independent board members; interested directors recused.
• ·Innervate's neuroblastoma program advancing toward pivotal efficacy/safety study and regulatory submission.
• ·Potential for Rare Pediatric Disease Priority Review Voucher, though no assurance of receipt or monetization.

04-05-2026

Viatris Inc. announced that Chief Financial Officer Theodora 'Doretta' Mistras will depart for a new opportunity, remaining with the company until May 22, 2026, while Paul Campbell, current Chief Accounting Officer and Corporate Controller, is named Interim CFO effective May 8, 2026. CEO Scott A. Smith thanked Mistras for her contributions toward sustainable growth and expressed confidence in Campbell's expertise to ensure continuity and operational discipline. The company plans to release Q1 2026 financial results on May 7, 2026, with a conference call at 8:30 a.m. ET.

• ·Campbell joined Viatris' legacy company Mylan in 2002 and brings over two decades of experience.
• ·Campbell previously served nearly a decade at Deloitte & Touche as a Senior Manager in Audit.
• ·Campbell holds a Bachelor of Science in Accounting from Pennsylvania State University.

04-05-2026

SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement (MSA) with Emergent BioSolutions Canada Inc. on April 28, 2026, for clinical and commercial manufacturing services of SAB-142 at Emergent’s facility in Canada. The MSA has a 5-year term commencing upon FDA approval of SAB-142, with a minimum aggregate spend of $36 million post-approval. Emergent holds exclusive manufacturing rights during the term, though SAB may establish limited alternative sources.

• ·MSA term may be extended by mutual amendment prior to expiration.
• ·Termination possible by either party for insolvency, material breach (30-90 day cure), non-payment (by Emergent), mutual agreement, or force majeure (90 days).
• ·Upon certain terminations by Emergent, SAB must pay minimum annual spend for remaining years less saved costs.
• ·Pricing for commercial batches and development services to be set in future amendments or statements of work, with annual adjustments.

04-05-2026

Pool Corporation announced a leadership transition effective May 4, 2026, appointing John B. Watwood as President and CEO, succeeding Peter D. Arvan who is stepping down from those roles and the Board after nine years; John E. Stokely was appointed Executive Chair. The company reaffirmed its full-year 2026 guidance as previously provided on April 23, 2026, but postponed its Investor Day originally scheduled for May 12, 2026. No changes to strategic priorities or operations were indicated.

• ·John B. Watwood joined POOLCORP as Executive Vice President in January 2026.
• ·Peter D. Arvan served in his roles for nine years.
• ·John E. Stokely has served on the Board since 2000, as Lead Independent Director since 2003, and as Chair since 2017.

04-05-2026

PSQ Holdings, Inc. entered into a Severance Agreement and General Release with James Rinn, effective April 30, 2026, as disclosed in this 8-K filing under Item 5.02. The agreement is attached as Exhibit 10.1. The report was signed by Jim Giudice, Chief Legal Officer, on May 4, 2026.

• ·XBRL identifiers include Class A Common Stock (par value $0.0001 per share) and Redeemable Warrants (exercisable at $11.50 per share)
• ·Event dated April 29, 2026 in XBRL tags